A 50 mg vial of tirzepatide provides high-capacity, lyophilized research-grade material designed for extended high-throughput in vitro assays and preclinical animal models. Synthesized under strict quality controls, each 50mg tirzepatide format ensures superior analytical purity (>99%) and minimal lot-to-lot variability for quantitative investigations into dual GIP/GLP-1 receptor co-agonist signaling pathways.
A 50 mg vial of tirzepatide provides high-capacity, lyophilized research-grade material designed for extended high-throughput in vitro assays and preclinical animal models. Synthesized under strict quality controls, each 50mg tirzepatide format ensures superior analytical purity (>99%) and minimal lot-to-lot variability for quantitative investigations into dual GIP/GLP-1 receptor co-agonist signaling pathways.
In modern bioenergetic and metabolic research, the 50 mg vial of tirzepatide represents a high-yield format tailored for laboratory facilities requiring substantial chemical mass for multi-week cellular protocols and quantitative animal assays. Tirzepatide is a synthetic 39-amino-acid peptide engineered to act as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its primary primary structure is based on the native GIP sequence, modified with a C18 fatty diacid acyl chain attached via a linker at the Lys20 residue, facilitating reversible binding to plasma albumin and extending its biological half-life in experimental models.
Researchers utilizing the 50mg tirzepatide concentration format often focus on how dual receptor co-stimulation influences intracellular cyclic adenosine monophosphate (cAMP) accumulation, pancreatic beta-cell insulin secretion dynamics, and central nervous system satiety pathways. By supplying 50 milligrams of active peptide in a single lyophilized glass matrix, laboratory investigators can maintain unified reagent lots across large experimental cohorts, minimizing batch-to-batch analytical variance during longitudinal research programs accessible through our comprehensive research library.
The molecular mechanics of tirzepatide hinge on its unique balance between GIP and GLP-1 receptor activation profiles. In vitro functional assays demonstrate that tirzepatide possesses full agonist activity at the GIP receptor comparable to native human GIP, while exhibiting biased agonist behavior at the GLP-1 receptor, favoring cAMP generation over beta-arrestin recruitment. This selective signaling bias is postulated in preclinical literature to attenuate receptor desensitization and internalization, allowing for sustained downstream signaling cascades.
When examining high-density research vials, such as the tirzepatide 50mg vial, laboratories examine how the C18 diacid moiety impacts lipophilic interactions within target membrane microdomains. Preclinical rodent models indicate that dual co-activation leads to superior reductions in body mass, enhanced glucose tolerance, and altered lipid metabolism compared to selective single-receptor agonists. Investigating these dual-pathway interactions requires pure, unadulterated peptide preparations capable of delivering predictable concentrations in receptor binding kinetic studies.
Quality assurance for high-mass peptides is critical to preventing background interference in enzymatic, cellular, or animal assays. Every 50 mg vial of tirzepatide manufactured for PX1 Research undergoes rigorous verification protocols to ensure analytical integrity. Chemical identity and purity are established through high-performance liquid chromatography (RP-HPLC) paired with electrospray ionization mass spectrometry (ESI-MS). Each lot must meet or exceed a strictly defined 99.0% chromatographic purity threshold.
Furthermore, biological assays require absolute minimal background contaminants. Bacterial endotoxins—specifically lipopolysaccharides (LPS) derived from Gram-negative expression vectors or handling equipment—can inadvertently induce inflammatory cascades in cellular cultures and rodent tissue, corrupting experimental readouts. PX1 Research subjects all lot batches to Chromogenic Recombinant Factor C or Limulus Amebocyte Lysate (LAL) testing, guaranteeing endotoxin levels strictly under 0.5 EU/mg. Every purchase includes access to a lot-specific, downloadable Certificate of Analysis (COA) generated by an independent ISO 17025 accredited analytical laboratory.
When evaluating vendors for critical research reagents, academic and commercial research groups must look beyond simple mass measurements and evaluate verifiable manufacturing standards. Sourcing high-yield formats like the tirzepatide 50 mg vial requires strict adherence to cold-chain logistics, lot traceability, and chemical stability standards.
PX1 Research maintains complete domestic manufacturing oversight within GMP-compliant facilities located in the USA. Orders ship directly from fulfillment nodes in California and Arizona, utilizing same-day dispatch for orders finalized before standard afternoon cutoffs (Monday through Friday). This infrastructure minimizes ambient transit times, preserving the structural stability of delicate lyophilized peptide matrices prior to laboratory reconstitution.
To understand the relative potency and target engagement of dual GIP/GLP-1 co-agonists, researchers often run parallel comparative trials against single-target or multi-target incretin mimetics. For example, comparing the 50mg tirzepatide sequence against single-target GLP-1 receptor agonists such as Semaglutide 10mg allows investigators to isolate the specific additive contribution of GIP receptor activation on metabolic parameters and gene expression profiles.
Similarly, emerging studies compare tirzepatide against triple-agonist research constructs like Retatrutide 10mg, which incorporates glucagon receptor (GCGR) activity alongside GIP and GLP-1 targets, or non-incretin satiety modulators like Cagrilintide 5mg. Utilizing uniform concentration standards across these peptide classes ensures precise molar comparisons in competitive radioligand binding assays and cellular signal transduction experiments. Explore our full catalog of GLP-1 and GIP dual agonists to select appropriate comparative controls.
Proper reconstitution of a tirzepatide 50mg vial is essential for maintaining peptide solubility and preventing mechanical shear degradation. Given the substantial mass contained within a 50 mg vial, liquid volume management must be calculated based on desired working stock concentrations. Reconstitution should always occur in a sterile laminar flow hood using aseptic techniques.
For long-term multi-use stock solutions intended for in vitro assays, researchers frequently employ sterile bacteriostatic water containing 0.9% benzyl alcohol, or sterile phosphate-buffered saline (PBS, pH 7.4) for immediate downstream cellular applications. The diluent should be introduced slowly along the glass wall of the vial rather than sprayed directly onto the lyophilized cake. Gentle side-to-side rotation or slow inversion is recommended to achieve complete dissolution; vortexing or high-energy mechanical shaking must be avoided to prevent protein aggregation and peptide denaturation. Detailed volumetric calculations can be streamlined using our online peptide reconstitution calculator.
In its un-reconstituted, lyophilized state, a 50 mg vial of tirzepatide should be stored at -20°C in a desiccated environment protected from direct light exposure. Under these conditions, the dry peptide matrix remains stable for up to 24 months without measurable chemical degradation or loss of biological activity.
Once reconstituted into aqueous solution, working stocks should be aliquoted into sterile, low-protein-binding microcentrifuge tubes to prevent adsorption loss onto container walls. Aliquots intended for short-term use (up to 28 days) can be maintained under refrigeration at 2°C to 8°C if preserved with bacteriostatic agents. Reconstituted stock without antimicrobial preservatives must be used immediately or stored frozen at -80°C. Repeated freeze-thaw cycles must be strictly avoided, as thermal cycling causes physical stress that induces oligomerization and chemical cleavage.
The high-mass 50mg tirzepatide vial is specifically engineered to support resource-intensive research settings. In cellular biology, high concentrations of stock solutions are required for saturation binding kinetics, receptor down-regulation assays, and transcriptome profiling across various metabolic tissue cultures (e.g., primary hepatocytes, 3T3-L1 adipocytes, and INS-1 pancreatic beta-cell lines).
In rodent models of metabolic dysfunction (such as ob/ob, db/db, or diet-induced obesity mice), research protocols often require chronic daily or weekly administration across multi-week timeframes. Sourcing a 50 mg vial ensures that all animals within a given experimental block receive treatment from a single, uniform production batch, effectively eliminating lot-based variance in therapeutic signal magnitude. Academic and industrial labs interested in large-scale procurement can review options via our dedicated wholesale institutional account portal.
What is a 50 mg vial of tirzepatide used for in preclinical research?
A 50 mg vial of tirzepatide is utilized in laboratory settings for in vitro receptor binding assays, cell culture signaling studies, and preclinical animal models evaluating dual GIP/GLP-1 receptor activation, metabolic homeostasis, and beta-cell function. It is intended strictly for laboratory research use.
How is 50mg tirzepatide validated for purity and identity?
Every 50mg tirzepatide lot is subjected to RP-HPLC (Reverse-Phase High-Performance Liquid Chromatography) to confirm >99% purity and ESI-MS (Electrospray Ionization Mass Spectrometry) to verify precise molecular weight. Independent third-party ISO 17025 accredited labs issue a lot-specific Certificate of Analysis (COA) for each batch.
What is the advantage of procuring a tirzepatide 50 mg vial over smaller unit sizes?
The high-capacity tirzepatide 50 mg vial allows research laboratories running high-throughput screening or extended animal study cohorts to utilize a single consistent batch of peptide. This eliminates lot-to-lot analytical variance across long-term experimental timelines.
How should a tirzepatide 50mg vial be reconstituted in a laboratory setting?
Reconstitution of a tirzepatide 50mg vial should be performed under a sterile laminar flow hood. A compatible diluent, such as bacteriostatic water or sterile buffer, should be introduced slowly down the interior glass wall. The vial should be gently swirled until completely dissolved, avoiding vigorous vortexing.
What are the recommended storage parameters for high-capacity tirzepatide vials?
Lyophilized vials should be stored at -20°C in a dry, dark environment. Upon reconstitution, working solutions should be divided into single-use aliquots in low-binding tubes and stored at -80°C for long-term preservation or 2°C–8°C for short-term active use (if using bacteriostatic solvent).
What endotoxin levels are acceptable for a 50 mg vial of tirzepatide?
PX1 Research mandates that endotoxin levels for every 50 mg vial of tirzepatide remain strictly under 0.5 EU/mg, as verified by LAL or Recombinant Factor C testing, preventing endotoxin-induced background artifacts in cell and animal assays.
How does tirzepatide compare to single-receptor GLP-1 agonists in in vitro models?
In vitro signaling assays indicate that tirzepatide functions as a dual GIP/GLP-1 receptor co-agonist, exhibiting full potency at the GIP receptor and biased cAMP signaling at the GLP-1 receptor, whereas single agonists engage only the GLP-1 pathway.
What solvent vectors are compatible with tirzepatide for cell culture studies?
Tirzepatide is soluble in aqueous buffers such as phosphate-buffered saline (PBS, pH 7.4), tris-buffered saline (TBS), or sterile water. For cell culture assays requiring non-preservative media, fresh reconstitution in sterile PBS is recommended.
How does PX1 Research ensure lot-to-lot consistency for bulk research orders?
PX1 Research enforces strict US-based synthesis protocols under GMP-compliant standards, verifying every lot through automated HPLC purification and third-party analytical COAs before release.
Can high-concentration tirzepatide stock solutions undergo repeated freeze-thaw cycles?
No. Repeated freeze-thaw cycles degrade peptide structural integrity and promote aggregation. Reconstituted stock solutions should be aliquoted into single-use research volumes prior to freezing.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.